The current study was conducted to determine the feasibility of cytologically clearing the bladder of tumor cells after transurethral resection of bladder tumor (TURBT) and aggressive serial bladder washing. METHODS: A prospective pilot sample of 20 patients with known bladder masses was enrolled before undergoing TURBT. Preoperative cytology and 4 postoperative cytology specimens were assessed for malignant cells between serial bladder washes.
INTRODUCTION
Urothelial cell carcinoma of the bladder is the third most common malignancy diagnosed in men and the 11th most common cancer diagnosed among women in the United States. 1 Patients with urothelial cell carcinoma of the lower tract routinely require imaging of the upper urinary tract to assess for multifocal disease. 2 However, occasionally, conditions exist that preclude such contrast-based studies (ie, contrast dye allergy or renal insufficiency). In such situations, upper tract studies are accomplished with cystoscopy and direct retrograde injection of contrast to obtain a pyelogram. Historically, urologists are taught not to perform such retrograde studies or retrograde treatment of upper tract urolithiasis in the presence of a bladder tumor secondary to the theoretical risk of upper urinary tract seeding by tumor cells. Prior reports have demonstrated the risk of upper urinary tract seeding and cancer development to be 15-fold to 22-fold greater in patients with bladder cancer with concomitant vesicoureteral reflux compared with those without reflux. 3, 4 The theoretical benefit of singledose intravesical chemotherapy after transurethral resection of bladder tumor (TURBT) is based on the concept that free-floating tumor cells are at risk of implanting in new sites. 5 In the current study, we hypothesized that it may be possible to clear the bladder of malignant cells after a complete TURBT through serial washings, thereby reassuring the surgeon of the oncologic safety of proceeding with upper tract instrumentation. Therefore, we used cytology at the time of TURBT to determine feasibility and the number of bladder washes required to completely clear the malignant cells.
MATERIALS AND METHODS
After Institutional Review Board approval, 24 patients undergoing TURBT at Virginia Mason Medical Center in Seattle, Washington were prospectively enrolled between December 2014 and October 2015. The primary endpoint of this descriptive proof-of-principle pilot study was cytology results after serial bladder barbotage, and the number of washes needed to achieve cytologic clearance. A secondary endpoint was the surgeon's ability to determine tumor grade by cystoscopic examination at the time of TURBT. Patients aged > 18 years with at least 1 bladder tumor requiring surgical resection were eligible for the current study. Patients who were to undergo biopsy without complete tumor resection were excluded.
Initial urine cytology (cytology specimen 1) was obtained before bladder tumor resection in the operating room. The surgeon predicted tumor grade and stage of disease visually before TURBT. The ability to visually grade tumors was assessed because there is limited sensitivity of cytopathology for low-grade urothelial carcinoma. 6 Thus, we expected to more aptly measure cytologic clearance in those individuals with high-grade disease. Using a 30-degree lens and standard white light cystoscopy, the bladder tumor was then completely resected. The type of resection current (monopolar vs bipolar) and the use of cold-cup biopsy forceps for bladder lesions were determined as per surgeon preference. After resecting all visible tumor, a second urine cytology was obtained immediately after TURBT (cytology specimen 2). Next, 3 consecutive bladder washes were performed with a cytology specimen after each (cytology specimens 3, 4, and 5). All washes were completed sequentially before reversal of anesthesia in the operating room immediately after TURBT. Normal saline was used as the bladder irrigation solution.
SurePath (Becton, Dickinson and Company, Franklin Lakes, NJ) slides were prepared by following the sample preparation and staining instructions as provided by the manufacturer (Fig. 1) . The slides were reviewed by a board certified cytopathologist (S.N.A.) who was blinded to the tumor pathology and cystoscopic findings. Slides were graded according to the Paris System for Reporting Urinary Cytology: nondiagnostic/unsatisfactory, negative for highgrade urothelial carcinoma, atypical urothelial cells, suspicious for high-grade urothelial carcinoma, high-grade urothelial carcinoma, and low-grade urothelial neoplasm.
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A board-certified genitourinary pathologist (S.N.A.) determined pathologic tumor characteristics (ie, volume, grade, and stage).
Statistical Analysis
The accuracy of the surgeon in determining tumor grade at the time of TURBT with white light cystoscopy was assessed for sensitivity, specificity, and the positive and negative predictive values. The 95% confidence intervals were calculated using the log method. All statistical analyses were performed using R (version 3.1.1.11; R Foundation, Vienna, Austria) and Stata (version 13.1; StataCorp LP, College Station, Tex) statistical software.
RESULTS
A total of 24 patients with bladder tumors were enrolled, with exclusions made as follows: 2 patients were excluded for incomplete TURBT and 2 for nonurothelial cell histology (1 patient with adenocarcinoma and 1 with a benign tumor), leaving 20 patients for analysis. Select patient demographics, clinical characteristics, and histologic findings are shown in Table 1 . The majority of patients were in their 70s (range, 54-92 years) and were undergoing TURBT for index tumors (Table 1) . Of the 8 patients with prior tumors (all of which were clinically staged as T1), 5 patients received prior intravesical therapy. The majority of patients were former smokers ( Table 1 ). The majority of tumors were multifocal (70%) ( Table 1) , with a mean final pathologic volume of 1.5 cm in situ was suspected (23%), but no cases were identified pathologically.
There may be a higher oncologic risk of upper tract seeding with high-grade compared with low-grade disease. In addition, cytology has different sensitivities for malignant cells based on histologic grade. Therefore, we reported the surgeon's ability to discriminate between low-grade and high-grade pathology visually with standard white light cystoscopy (Table 2) . Using histopathology as the gold standard, test performance characteristics of visual cystoscopic inspection are presented in Table 2 for both patients with high-grade and low-grade disease. It is important to note that approximately 15% of patients with high-grade disease were misclassified as having low-grade disease by visual cystoscopic evaluation alone, corresponding to a negative predictive value of 85% for high-grade disease (Table 2) .
Results regarding the feasibility and rate of cytopathologically clearing tumor cells with serial washes are shown in Table 3 , stratified by final pathologic grade. Only 3 low-grade tumors (25%) were cytologically abnormal before TURBT, as would be expected. No patients with low-grade histology were found to have positive cytology after TURBT. Among the 8 patients with high-grade disease, 6 (75%) had high-grade cytology immediately before TURBT and only 1 of these patients was cleared by serial washing, leaving 63% of patients with persistent high-grade cytology. The representative appearance of high-grade and benign cytology before and after TURBT are shown (Fig. 1) .
With regard to a possible effect of chemotherapy biasing cytology results, the median interval from intravesical therapy to on-study TURBT and serial bladder washing was 6 months (interquartile range, 4.5-24.5 months). Only 1 of these patients was found to have high-grade cytology at the time of TURBT/serial bladder washing and this occurred 34 months after intravesical therapy (a 6-cycle course of bacille Calmette-Guerin without maintenance). This patient also was the 1 individual whose high-grade cytology was rendered free of tumor cells after serial washing. Of the other 7 patients with high-grade urothelial carcinoma (8 patients in total), none had exposure to intravesical agents. Two of these 7 patients with high-grade urothelial carcinoma had recurrent high-grade tumors, whereas 5 of the patients had high-grade index tumors. It is interesting to note that for the 5 patients with prior exposure to intravesical therapy, the median number of prior disease recurrences was 3 (interquartile range, 3-5 disease recurrences). The majority of these patients were referred to the study center after receiving treatment elsewhere and therefore the tumor grade was known only for the most recent disease recurrence. We conclude that those receiving therapy with bacille Calmette-Guerin had a high-grade or in situ lesion at some point. With regard to the most recent histology, 4 of 5 tumors were low grade.
DISCUSSION
The current study is a prospective pilot study regarding the feasibility of eliminating tumor cells as detected by cytology after TURBT. We found a differential effect by final pathologic grade. Among those patients with positive cytology before undergoing TURBT, none with confirmed low-grade pathology had persistently positive cytology. However, among those individuals with high-grade disease, only 1 such patient was cleared after TURBT with serial bladder washings. Thus, we conclude that in the setting of high-grade urothelial cancer, malignant cells persist after aggressive serial bladder washing aimed at cytologic clearance.
Given our ability in the current study to cytologically detect persistent malignant cells after TURBT and serial bladder washing, instrumentation of the upper urinary tract may pose a theoretical risk of tumor seeding. In the subset of patients with histologically low-grade disease, the results of the current study confirm the findings of several recent publications noting the relative inaccuracy of urinary cytology in identifying malignancy. 6 Thus, we cannot draw conclusions regarding the feasibility of clearing malignant cells within the setting of low-grade urothelial carcinoma. A conservative approach is to perform indicated upper tract procedures only after clearing the bladder of malignancy, regardless of tumor grade, and allow for adequate healing time in those patients who are ineligible for antegrade imaging. The practical impact of these findings hinges on the assumption that upper tract instrumentation within the setting of cytologically malignant cells may pose an oncologic risk to the patient. After TURBT, dislodged tumor cells are believed to be a main culprit in the high rate of disease recurrence and are the rational basis for immediate postoperative intravesical therapy. 5, 8 The mechanism of implantation of tumor cells is theorized to be due to decreased urothelial integrity in the setting of injury.
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Studies examining contrast effects on viable tumor cells have demonstrated continued viability despite exposure to contrast material, although this is decreased with agents of higher ionic and osmolar strength. 11, 12 Similarly, several studies have demonstrated an association between postsurgical positive cytology and urothelial tumor recurrence for both TURBT 13 and radical nephroureterectomy. 14 Finally, 2 studies examined the inverse principle and demonstrated that ureteroscopy of the upper tract within the setting of high-grade urothelial carcinoma is associated with intravesical recurrences, with a likely mechanism of high pressure irrigation in the upper tract dislodging high-grade cells, resulting in lower tract implantation. 15, 16 These observations, taken together, suggest that although the theoretical risk may be low, within the setting of positive cytology, viable tumor cells are likely to be present in the bladder and could result in upper tract implantation, especially within the setting of urothelial trauma. Future work to validate the urothelial injury concept further could be achieved in a cohort of patients undergoing random Urothelial Ca Cells and Serial Wash at TURBT/Macleod et al
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bladder biopsies for positive cytology to determine an association with disease recurrence in the biopsy sites. Additional validation could include comparison of outcomes for patients who do/do not undergo concomitant upper tract instrumentation at the time of TURBT. There are several limitations to the current study that need to be acknowledged to place this study within the appropriate context. This is a small, single-institution sample of patients whose tumor characteristics and risk stratification may not be applicable to all patients with bladder cancer. In addition, only 8 of the 20 patients (40%) had high-grade disease, and these patients are the most relevant subgroup and the group for whom cytology is most likely to be a valid metric of tumor cell persistence. However, the sample and data were accrued prospectively, thereby eliminating biases associated with retrospective chart review, and the cohort had demographics that were similar to those of the general population with bladder cancer. Given that urothelial cancer is consistently reported as a panurothelial field defect, 17 we cannot completely rule out undiagnosed carcinoma in situ, especially in the upper tract, as the source of cytologic tumor cell persistence. However, even if carcinoma in situ at another site was the source, the principle that malignant cells are not cleared by serial washing remains unchanged. In addition, it is not likely all observed patients with persistent positive cytology had concomitant carcinoma in situ in the upper tract. We relied on standard white light cystoscopy and cytology for the current study, and do not compare this technology with emerging techniques in enhanced cystoscopic bladder imaging or a variety of available urinary tumor markers. Despite these limitations, the objective of establishing the feasibility (or nonfeasibility) of clearing cytologically positive tumor cells from the bladder through washing after TURBT was met.
We demonstrated that up to 63% of those patients with high-grade bladder lesions will continue to have positive cytology despite undergoing a visually complete TURBT and aggressive washing. This finding is in accord with sage oncologic principles that are inculcated into Original Article urologists during training, despite the paucity of supporting scientific data. Moving forward, efforts directed at developing a highly accurate and rapid urinary marker for persistent malignant cells could be used to determine the safety of upper tract instrumentation after TURBT. Similarly, animal models could elucidate the biologic ability of urine with persistent positive cytology to induce tumors in new urothelial sites, to conclude the magnitude of risk posed by instrumentation in this setting.
Conclusions
The results of the current pilot study of the feasibility of clearing the bladder of cytologically malignant cells through serial barbotage indicate that, in the setting of high-grade disease, malignant cells persist despite vigorous washing. As expected, we confirmed that in patients with low-grade urothelial cancer, urine cytology is rarely positive. Until more data are available regarding the magnitude of risk posed by free-floating malignant cells detected by cytology after TURBT, the safest oncologic approach is to avoid concomitant instrumentation of the upper urinary tract at the time of bladder tumor resection.
